Refractory fallopian tube carcinoma – current perspectives in pathogenesis and management

References

• StewartSLWikeJMFosterSLMichaudFThe incidence of primary fallopian tube cancer in the United StatesGynecol Oncol2007107339239717961642
   PubMed Web of Science ®Google Scholar
• GoodmanMTShvetsovYBIncidence of ovarian, peritoneal, and fallopian tube carcinomas in the United States, 1995–2004Cancer Epidemiol Biomarkers Prev200918113213919124490
   PubMed Web of Science ®Google Scholar
• BerekJSCrumCFriedlanderMCancer of the ovary, fallopian tube, and peritoneumInt J Gynaecol Obstet2012119Suppl 2S118S12922999503
   PubMed Web of Science ®Google Scholar
• CrumCPDrapkinRKindelbergerDMedeirosFMironALeeYLessons from BRCA: the tubal fimbria emerges as an origin for pelvic serous cancerClin Med Res200751354417456833
   PubMedGoogle Scholar
• CrumCPDrapkinRMironAThe distal fallopian tube: a new model for pelvic serous carcinogenesisCurr Opin Obstet Gynecol20071913917218844
   PubMed Web of Science ®Google Scholar
• KatabuchiHOkamuraHCell biology of human ovarian surface epithelial cells and ovarian carcinogenesisMed Electron Microsc2003362748612886939
   PubMedGoogle Scholar
• HennessyBTColemanRLMarkmanMOvarian cancerLancet200937496981371138219793610
   PubMed Web of Science ®Google Scholar
• CheneGDauplatJRadosevic-RobinNCayreAPenault-LlorcaFTu-be or not tu-be: that is the question … about serous ovarian carcinogenesisCrit Rev Oncol Hematol201388113414323523591
   PubMed Web of Science ®Google Scholar
• FathallaMFIncessant ovulation – a factor in ovarian neoplasia?Lancet1971277161634104488
   PubMed Web of Science ®Google Scholar
• CaseyMJBewtraCHoehneLLTatpatiADLynchHTWatsonPHistology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindredsGynecol Oncol2000783 Pt 127828710985881
   PubMed Web of Science ®Google Scholar
• BarakatRRFedericiMGSaigoPERobsonMEOffitKBoydJAbsence of premalignant histologic, molecular, or cell biologic alterations in prophylactic oophorectomy specimens from BRCA1 heterozygotesCancer200089238339010918170
   PubMed Web of Science ®Google Scholar
• KesslerMFotopoulouCMeyerTThe molecular fingerprint of high grade serous ovarian cancer reflects its fallopian tube originInt J Mol Sci20131446571659623528888
   PubMed Web of Science ®Google Scholar
• CallahanMJCrumCPMedeirosFPrimary fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reductionJ Clin Oncol200725253985399017761984
   PubMed Web of Science ®Google Scholar
• KindelbergerDWLeeYMironAIntraepithelial carcinoma of the fimbria and pelvic serous carcinoma: Evidence for a causal relationshipAm J Surg Pathol200731216116917255760
   PubMed Web of Science ®Google Scholar
• FolkinsAKJarboeEASaleemuddinAA candidate precursor to pelvic serous cancer (p53 signature) and its prevalence in ovaries and fallopian tubes from women with BRCA mutationsGynecol Oncol2008109216817318342932
   PubMed Web of Science ®Google Scholar
• JarboeEAFolkinsAKDrapkinRInceTAAgostonESCrumCPTubal and ovarian pathways to pelvic epithelial cancer: a pathological perspectiveHistopathology200853212713818298580
   PubMed Web of Science ®Google Scholar
• CrumCPIntercepting pelvic cancer in the distal fallopian tube: theories and realitiesMol Oncol20093216517019383378
   PubMed Web of Science ®Google Scholar
• FolkinsAKJarboeEARohMHCrumCPPrecursors to pelvic serous carcinoma and their clinical implicationsGynecol Oncol2009113339139619237187
   PubMed Web of Science ®Google Scholar
• ChenEYMehraKMehradMSecretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tubeJ Pathol2010222111011620597068
   PubMed Web of Science ®Google Scholar
• KurmanRJShihIMMolecular pathogenesis and extraovarian origin of epithelial ovarian cancer – shifting the paradigmHum Pathol201142791893121683865
   PubMed Web of Science ®Google Scholar
• LeblancENarducciFFarreIRadical fimbriectomy: a reasonable temporary risk-reducing surgery for selected women with a germ line mutation of BRCA 1 or 2 genes? Rationale and preliminary developmentGynecol Oncol2011121347247621411127
   PubMed Web of Science ®Google Scholar
• LeonhardtKEinenkelJSohrSEngelandKHornLCp53 signature and serous tubal in-situ carcinoma in cases of primary tubal and peritoneal carcinomas and serous borderline tumors of the ovaryInt J Gynecol Pathol201130541742421804388
   PubMed Web of Science ®Google Scholar
• CrumCPMcKeonFDXianWThe oviduct and ovarian cancer: causality, clinical implications, and “targeted prevention”Clin Obstet Gynecol2012551243522343226
   PubMed Web of Science ®Google Scholar
• MingelsMJRoelofsenTvan der LaakJATubal epithelial lesions in salpingo-oophorectomy specimens of BRCA-mutation carriers and controlsGynecol Oncol20121271889322710074
   PubMed Web of Science ®Google Scholar
• GaoFFBhargavaRYangHLiZZhaoCClinicopathologic study of serous tubal intraepithelial carcinoma with invasive carcinoma: is serous tubal intraepithelial carcinoma a reliable feature for determining the organ of origin?Hum Pathol20134481534154323465279
   PubMed Web of Science ®Google Scholar
• O’ShannessyDJJacksonSMTwineNCGene expression analyses support fallopian tube epithelium as the cell of origin of epithelial ovarian cancerInt J Mol Sci2013147136871370323880844
   PubMed Web of Science ®Google Scholar
• ReitsmaWde BockGHOosterwijkJCBartJHollemaHMouritsMJSupport of the ‘fallopian tube hypothesis’ in a prospective series of risk-reducing salpingo-oophorectomy specimensEur J Cancer201349113214122921157
   PubMed Web of Science ®Google Scholar
• RohMHKindelbergerDCrumCPSerous tubal intraepithelial carcinoma and the dominant ovarian mass: clues to serous tumor origin?Am J Surg Pathol200933337638319011565
   PubMed Web of Science ®Google Scholar
• MehraKMehradMNingGSTICS, SCOUTs and p53 signatures; a new language for pelvic serous carcinogenesisFront Biosci (Elite Ed)2011362563421196340
   PubMedGoogle Scholar
• LeeYMironADrapkinRA candidate precursor to serous carcinoma that originates in the distal fallopian tubeJ Pathol20072111263517117391
   PubMed Web of Science ®Google Scholar
• GrossALKurmanRJVangRShihIeMVisvanathanKPrecursor lesions of high-grade serous ovarian carcinoma: morphological and molecular characteristicsJ Oncol2010201012629520445756
   PubMedGoogle Scholar
• ShenHFridleyBLSongHPRACTICAL ConsortiumAustralian Ovarian Cancer Study GroupAustralian Cancer StudyEpigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancerNat Commun20134162823535649
   PubMed Web of Science ®Google Scholar
• HutsonRRamsdaleJWellsMp53 protein expression in putative precursor lesions of epithelial ovarian cancerHistopathology19952743673718847068
   PubMed Web of Science ®Google Scholar
• MarquezRTBaggerlyKAPattersonAPPatterns of gene expression in different histotypes of epithelial ovarian cancer correlate with those in normal fallopian tube, endometrium, and colonClin Cancer Res200511176116612616144910
   PubMed Web of Science ®Google Scholar
• WiegandKCShahSPAl-AghaOMARID1A mutations in endometriosis-associated ovarian carcinomasN Engl J Med2010363161532154320942669
   PubMed Web of Science ®Google Scholar
• LoweryWJSchildkrautJMAkushevichLLoss of ARID1A-associated protein expression is a frequent event in clear cell and endometrioid ovarian cancersInt J Gynecol Cancer201222191422193641
   PubMed Web of Science ®Google Scholar
• AyhanAMaoTLSeckinTLoss of ARID1A expression is an early molecular event in tumor progression from ovarian endometriotic cyst to clear cell and endometrioid carcinomaInt J Gynecol Cancer20122281310131522976498
   PubMed Web of Science ®Google Scholar
• LeeperKGarciaRSwisherEGoffBGreerBPaleyPPathologic findings in prophylactic oophorectomy specimens in high-risk womenGynecol Oncol2002871525612468342
   PubMed Web of Science ®Google Scholar
• LeeYMedeirosFKindelbergerDCallahanMJMutoMGCrumCPAdvances in the recognition of tubal intraepithelial carcinoma: applications to cancer screening and the pathogenesis of ovarian cancerAdv Anat Pathol20061311716462151
   PubMed Web of Science ®Google Scholar
• PowellCBKenleyEChenLMRisk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancyJ Clin Oncol200523112713215625367
   PubMed Web of Science ®Google Scholar
• FinchAShawPRosenBMurphyJNarodSAColganTJClinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriersGynecol Oncol20061001586416137750
   PubMed Web of Science ®Google Scholar
• SeidmanJDZhaoPYemelyanovaA“Primary peritoneal” high-grade serous carcinoma is very likely metastatic from serous tubal intraepithelial carcinoma: assessing the new paradigm of ovarian and pelvic serous carcinogenesis and its implications for screening for ovarian cancerGynecol Oncol2011120347047321159368
   PubMed Web of Science ®Google Scholar
• YatesMSMeyerLADeaversMTMicroscopic and early-stage ovarian cancers in BRCA1/2 mutation carriers: building a model for early BRCA-associated tumorigenesisCancer Prev Res (Phila)20114346347021278312
   PubMed Web of Science ®Google Scholar
• MorganRJAlvarezRDArmstrongDKNational Comprehensive Cancer NetworkOvarian cancer, version 3.2012J Natl Compr Canc Netw201210111339134923138163
   PubMed Web of Science ®Google Scholar
• OzolsRFBundyBNGreerBEGynecologic Oncology GroupPhase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group studyJ Clin Oncol200321173194320012860964
   PubMed Web of Science ®Google Scholar
• ArmstrongDKBundyBWenzelLGynecologic Oncology GroupIntraperitoneal cisplatin and paclitaxel in ovarian cancerN Engl J Med20063541344316394300
   PubMed Web of Science ®Google Scholar
• MarkmanMMoonJWilczynskiSSingle agent carboplatin versus carboplatin plus pegylated liposomal doxorubicin in recurrent ovarian cancer: final survival results of a SWOG (S0200) phase 3 randomized trialGynecol Oncol2010116332332520044128
   PubMed Web of Science ®Google Scholar
• BurgerRABradyMFBookmanMAGynecologic Oncology GroupIncorporation of bevacizumab in the primary treatment of ovarian cancerN Engl J Med2011365262473248322204724
   PubMed Web of Science ®Google Scholar
• PerrenTJSwartAMPfistererJICON7 InvestigatorsA phase 3 trial of bevacizumab in ovarian cancerN Engl J Med2011365262484249622204725
   PubMed Web of Science ®Google Scholar
• AghajanianCBlankSVGoffBAOCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancerJ Clin Oncol201230172039204522529265
   PubMed Web of Science ®Google Scholar
• AlbertsDSLiuPYHanniganEVIntraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancerN Engl J Med199633526195019558960474
   PubMed Web of Science ®Google Scholar
• GordonANTondaMSunSRackoffWDoxil Study 30–49 InvestigatorsLong-term survival advantage for women treated with pegylated liposomal doxorubicin compared with topotecan in a phase 3 randomized study of recurrent and refractory epithelial ovarian cancerGynecol Oncol20049511815385103
   PubMed Web of Science ®Google Scholar
• PiccartMJBertelsenKJamesKRandomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year resultsJ Natl Cancer Inst200092969970810793106
   PubMed Web of Science ®Google Scholar
• SchilderRJBradyWELankesHAPhase II evaluation of dasatinib in the treatment of recurrent or persistent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group studyGynecol Oncol20121271707422710075
   PubMed Web of Science ®Google Scholar
• SeamonLGRichardsonDLCopelandLJEvolution of the Gynecologic Oncology Group protocols in the treatment of epithelial ovarian cancerClin Obstet Gynecol201255113115522343234
   PubMed Web of Science ®Google Scholar
• BookmanMAGreerBEOzolsRFOptimal therapy of advanced ovarian cancer: carboplatin and paclitaxel vs cisplatin and paclitaxel (GOG 158) and an update on GOG0 182-ICON5Int J Gynecol Cancer200313673574014675308
   PubMed Web of Science ®Google Scholar
• KatsumataNYasudaMTakahashiFJapanese Gynecologic Oncology GroupDose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trialLancet200937496981331133819767092
   PubMed Web of Science ®Google Scholar
• KatsumataNYasudaMIsonishiSJapanese Gynecologic Oncology GroupLong-term results of dose-dense paclitaxel and carboplatin versus conventional paclitaxel and carboplatin for treatment of advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer (JGOG 3016): a randomised, controlled, open-label trialLancet Oncol201314101020102623948349
   PubMed Web of Science ®Google Scholar
• VaseyPAJaysonGCGordonAScottish Gynaecological Cancer Trials GroupPhase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinomaJ Natl Cancer Inst200496221682169115547181
   PubMed Web of Science ®Google Scholar
• MarkmanMRothmanRHakesTSecond-line platinum therapy in patients with ovarian cancer previously treated with cisplatinJ Clin Oncol1991933893931999708
   PubMed Web of Science ®Google Scholar
• RosePGFuscoNFluellenLRodriguezMSecond-line therapy with paclitaxel and carboplatin for recurrent disease following first-line therapy with paclitaxel and platinum in ovarian or peritoneal carcinomaJ Clin Oncol1998164149414979552057
   PubMed Web of Science ®Google Scholar
• ParmarMKLedermannJAColomboNICON and AGO CollaboratorsPaclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trialLancet200336193752099210612826431
   PubMed Web of Science ®Google Scholar
• PfistererJPlanteMVergoteIAGO-OVARNCIC CTGEORTC GCGGemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCGJ Clin Oncol200624294699470716966687
   PubMed Web of Science ®Google Scholar
• WagnerUMarthCLargillierRFinal overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patientsBr J Cancer2012107458859122836511
   PubMed Web of Science ®Google Scholar
• GladieffLFerreroADe RauglaudreGCarboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: results from a subset analysis of the CALYPSO phase III trialAnn Oncol20122351185118921976386
   PubMed Web of Science ®Google Scholar
• LortholaryALargillierRWeberBGINECO group FranceWeekly paclitaxel as a single agent or in combination with carboplatin or weekly topotecan in patients with resistant ovarian cancer: the CARTAXHY randomized phase II trial from Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO)Ann Oncol201223234635221562072
   PubMed Web of Science ®Google Scholar
• TanguayJSAnsariJBuckleyLFernandoIEpithelial ovarian cancer: role of pegylated liposomal Doxorubicin in prolonging the platinum-free interval and cancer antigen 125 trends during treatmentInt J Gynecol Cancer200919336136619407560
   PubMed Web of Science ®Google Scholar
• GriffithsRWZeeYKEvansSOutcomes after multiple lines of chemotherapy for platinum-resistant epithelial cancers of the ovary, peritoneum, and fallopian tubeInt J Gynecol Cancer2011211586521178570
   PubMed Web of Science ®Google Scholar
• Pujade-LauraineHilpertFWeberBAURELIA InvestigatorsAURELIA: A randomized phase III trial evaluating bevacizumab (BEV) plus chemotherapy (CT) for platinum (PT)-resistant recurrent ovarian cancer (OC)J Clin Oncol201230Suppl 18 LBA5002. Abstract
   Google Scholar
• CannistraSAMatulonisUAPensonRTPhase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancerJ Clin Oncol200725335180518618024865
   PubMed Web of Science ®Google Scholar
• BurgerRASillMWMonkBJGreerBESoroskyJIPhase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group StudyJ Clin Oncol200725335165517118024863
   PubMed Web of Science ®Google Scholar
• GotliebWHAmantFAdvaniSIntravenous aflibercept for treatment of recurrent symptomatic malignant ascites in patients with advanced ovarian cancer: a phase 2, randomised, double-blind, placebo-controlled studyLancet Oncol201213215416222192729
   PubMed Web of Science ®Google Scholar
• UnderhillCToulmondeMBonnefoiHA review of PARP inhibitors: from bench to bedsideAnn Oncol201122226827920643861
   PubMed Web of Science ®Google Scholar
• McCabeNTurnerNCLordCJDeficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibitionCancer Res200666168109811516912188
   PubMed Web of Science ®Google Scholar
• BryantHESchultzNThomasHDSpecific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymeraseNature2005434703591391715829966
   PubMed Web of Science ®Google Scholar
• FongPCYapTABossDSPoly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free intervalJ Clin Oncol201028152512251920406929
   PubMed Web of Science ®Google Scholar
• AudehMWCarmichaelJPensonRTOral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trialLancet2010376973724525120609468
   PubMed Web of Science ®Google Scholar
• KayeSBLubinskiJMatulonisUPhase II, open-label, randomized, multicenter study comparing the efficacy and safety of olaparib, a poly (ADP-ribose) polymerase inhibitor, and pegylated liposomal doxorubicin in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancerJ Clin Oncol201230437237922203755
   PubMed Web of Science ®Google Scholar
• GelmonKATischkowitzMMackayHOlaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised studyLancet Oncol201112985286121862407
   PubMed Web of Science ®Google Scholar
• LedermannJHarterPGourleyCOlaparib maintenance therapy in platinum-sensitive relapsed ovarian cancerN Engl J Med2012366151382139222452356
   PubMed Web of Science ®Google Scholar
• LiuJFTolaneySMBirrerMA Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancerEur J Cancer201349142972297823810467
   PubMed Web of Science ®Google Scholar
• OtsukaIKamedaSHoshiKEarly detection of ovarian and fallopian tube cancer by examination of cytological samples from the endometrial cavityBr J Cancer2013109360360923868002
   PubMed Web of Science ®Google Scholar
• MarkmanMBlessingJRubinSCConnorJHanjaniPWaggonerSGynecologic Oncology GroupPhase II trial of weekly paclitaxel (80 mg/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group studyGynecol Oncol2006101343644016325893
   PubMed Web of Science ®Google Scholar
• FerrandinaGLudovisiMLorussoDPhase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancerJ Clin Oncol200826689089618281662
   PubMed Web of Science ®Google Scholar
• MutchDGOrlandoMGossTRandomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancerJ Clin Oncol200725192811281817602086
   PubMed Web of Science ®Google Scholar
• MillerDSBlessingJAKrasnerCNPhase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology GroupJ Clin Oncol200927162686269119332726
   PubMed Web of Science ®Google Scholar
• ColemanRLBradyWEMcMeekinDSA phase II evaluation of nanoparticle, albumin-bound (nab) paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer: a Gynecologic Oncology Group studyGynecol Oncol2011122111111521497382
   PubMed Web of Science ®Google Scholar
• RosePGBlessingJABallHGA phase II study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma: a Gynecologic Oncology Group studyGynecol Oncol200388213013512586591
   PubMed Web of Science ®Google Scholar
• RothenbergMLLiuPYWilczynskiSPhase II trial of vinorelbine for relapsed ovarian cancer: a Southwest Oncology Group studyGynecol Oncol200495350651215581954
   PubMed Web of Science ®Google Scholar
• MarkmanMHakesTReichmanBIfosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum-resistant diseaseJ Clin Oncol19921022432481732425
   PubMed Web of Science ®Google Scholar
• AlbertsDSJiangCLiuPYWilczynskiSMarkmanMRothenbergMLLong-term follow-up of a phase II trial of oral altretamine for consolidation of clinical complete remission in women with stage III epithelial ovarian cancer in the Southwest Oncology GroupInt J Gynecol Cancer200414222422815086720
   PubMed Web of Science ®Google Scholar
• MatulonisUABerlinSIvyPCediranib, an oral inhibitor of vascular endothelial growth factor receptor kinases, is an active drug in recurrent epithelial ovarian, fallopian tube, and peritoneal cancerJ Clin Oncol200927335601560619826113
   PubMed Web of Science ®Google Scholar
• FriedlanderMHancockKCRischinDA Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancerGynecol Oncol20101191323720584542
   PubMed Web of Science ®Google Scholar
• BehbakhtKSillMWDarcyKMPhase II trial of the mTOR inhibitor, temsirolimus and evaluation of circulating tumor cells and tumor biomarkers in persistent and recurrent epithelial ovarian and primary peritoneal malignancies: a Gynecologic Oncology Group studyGynecol Oncol20111231192621752435
   PubMed Web of Science ®Google Scholar
• MatulonisUASharmaSGhamandeSPhase II study of MLN8237 (alisertib), an investigational Aurora A kinase inhibitor, in patients with platinum-resistant or -refractory epithelial ovarian, fallopian tube, or primary peritoneal carcinomaGynecol Oncol20121271636922772063
   PubMed Web of Science ®Google Scholar
• ColomboNKutarskaEDimopoulosMRandomized, open-label, phase III study comparing patupilone (EPO906) with pegylated liposomal doxorubicin in platinum-refractory or -resistant patients with recurrent epithelial ovarian, primary fallopian tube, or primary peritoneal cancerJ Clin Oncol201230313841384722987083
   PubMed Web of Science ®Google Scholar
• CamposSMPensonRTMatulonisUA phase II trial of Sunitinib malate in recurrent and refractory ovarian, fallopian tube and peritoneal carcinomaGynecol Oncol2013128221522022885865
   PubMed Web of Science ®Google Scholar